Renan Rodrigues de Oliveira Silva

@info.fcf.usp.br

Department of Pharmaceutical and Biochemical Technology, School of Pharmaceutical Sciences
University of São Paulo



              

https://researchid.co/rrosilva

RESEARCH, TEACHING, or OTHER INTERESTS

Organic Chemistry, Fluid Flow and Transfer Processes, Process Chemistry and Technology, Drug Discovery

6

Scopus Publications

Scopus Publications

  • Optimization of 4-amino-pyridazin-3(2H)-one as a valid core scaffold for FABP4 inhibitors
    Giuseppe Floresta, Letizia Crocetti, Renan Rodrigues de Oliveira Silva, Vincenzo Patamia, Francesca Mazzacuva, Yu Chee Sonia Chen, Claudia Vergelli, and Agostino Cilibrizzi
    Wiley
    AbstractCurrent clinical research suggests that fatty acid‐binding protein 4 inhibitors (FABP4is), which are of biological and therapeutic interest, may show potential in treating cancer and other illnesses. We sought to uncover new structures through the optimization of the previously reported 4‐amino and 4‐ureido pyridazinone‐based series of FABP4is as part of a larger research effort to create more potent FABP4 inhibitors. This led to the identification of 14e as the most potent analog with IC50 = 1.57 μM, which is lower than the IC50 of the positive control. Advanced modeling investigations and in silico absorption, distribution, metabolism, and excretion ‐ toxicity calculations suggested that 14e represents a potential candidate for in vivo studies such as FABP4i.

  • Synthesis of Lobeglitazone intermediates seeking for continuous drug production in flow capillary microreactor
    Renan Rodrigues de Oliveira Silva, Paulo Victor Cuesta Calvo, Christian Adrian Merfels, Mikael Vitor Rodrigues Lima, Harrson S. Santana, Attilio Converti, and Mauri Sergio Alves Palma
    Elsevier BV

  • Ligand Growing Experiments Suggested 4-amino and 4-ureido pyridazin-3(2H)-one as Novel Scaffold for FABP4 Inhibition
    Letizia Crocetti, Giuseppe Floresta, Chiara Zagni, Divya Merugu, Francesca Mazzacuva, Renan Rodrigues de Oliveira Silva, Claudia Vergelli, Maria Paola Giovannoni, and Agostino Cilibrizzi
    MDPI AG
    Fatty acid binding protein (FABP4) inhibitors are of synthetic and therapeutic interest and ongoing clinical studies indicate that they may be a promise for the treatment of cancer, as well as other diseases. As part of a broader research effort to develop more effective FABP4 inhibitors, we sought to identify new structures through a two-step computing assisted molecular design based on the established scaffold of a co-crystallized ligand. Novel and potent FABP4 inhibitors have been developed using this approach and herein we report the synthesis, biological evaluation and molecular docking of the 4-amino and 4-ureido pyridazinone-based series.

  • How chemical engineers can contribute to fight the COVID-19
    Harrson S. Santana, Marcos R.P. de Souza, Mariana G.M. Lopes, Johmar Souza, Renan R.O. Silva, Mauri S.A. Palma, Wilson L.V. Nakano, Giovanni A.S. Lima, Guadalupe Munhoz, Dirceu Noriler,et al.
    Journal of the Taiwan Institute of Chemical Engineers Elsevier BV

  • Flow Synthesis of a Thiazolidine Drug Intermediate in Capillary Microreactors
    Renan Rodrigues de Oliveira Silva, Paulo Victor Cuesta Calvo, Milena Fernandes da Silva, Carlo Solisio, Attilio Converti, and Mauri Sergio Alves Palma
    Wiley
    AbstractMicroreactor technology can help to reduce the time to market new drugs. It was applied to produce (Z)‐5‐benzylidenethiazolidine‐2,4‐dione, a heterocyclic intermediate in the synthesis of various drugs. Ethanol was the optimum solvent and piperidine the best catalyst in the batch process. The continuous/microreactor process exhibited a much better performance than the batch process. The productivity, which was strongly influenced by solvent and temperature, reached a maximum at 160 °C using methanol as solvent. A kinetic/thermodynamic study indicated that the reaction followed the second‐order model and allowed estimating its main thermodynamic parameters. A product recovery protocol was finally proposed. The microreactor proved an efficient alternative to the batch reactor in scaling up the production of active pharmaceutical ingredients.

  • Microreactor Technology as a Tool for the Synthesis of a Glitazone Drug Intermediate
    Danilo da Silva Pinheiro, Renan Rodrigues de Oliveira Silva, Paulo Victor Cuesta Calvo, Milena Fernandes da Silva, Attilio Converti, and Mauri Sergio Alves Palma
    Wiley
    AbstractOne of the bottlenecks in the pharmaceutical industry is drug production scale‐up, which can be performed by microreactor technology. Such an approach was applied to the synthesis of (Z)‐5‐(4‐hydroxybenzylidene)thiazolidine‐2,4‐dione, a bioactive aromatic heterocyclic compound belonging to the class of glitazones. n‐Propanol was the best solvent and piperidine the best catalyst for the batch reaction, which was completed in only 5.5 h. In the microreactor, the productivity was almost independent of solvent. The microreactor behaved as a plug‐flow reactor and operated at a steady state for ten hours without efficiency loss. The results suggest that microreactors may replace batch reactors in scaling up drug production.